Feeling after watching "The Devil Child of Nezha"
Release time:
2020-07-22
Feeling after watching "The Devil's Child Comes into the World"
When referring to the Devil's Child, everyone may immediately think of the virtuous child who pierced two skyrocketing petals, but what is in the film "The Devil's Child Comes into the World" is not - with neat bangs, drooping balsam melon face, always invisible smoke makeup, walking, rough voice, the sign is the smile of evil spirits, which shows fierce light from time to time, completely subverting the image of Nezha in everyone's mind. Compared with "Father and Son Break, Love and Kill " in the old version of the story of sealing gods, this movie jumps out of the original framework and tells the story of a magic pill reincarnated with the label of "Magic Child " from birth, surrounded by prejudice and not recognized by the common people.
When I saw that Nezha saved the little girl, but no one believed it, I was beaten by the common people. When I saw that the dragon clan was considered a demon by the world and lived in "dragon palace " , which was not as good as the dungeon, when Shen Gongbao was a leopard spirit and his efforts were still not valued by the master, let a person really feel heartache - original fate of the greatest injustice, is from the world's prejudice! In my opinion, everyone has the right to choose to be himself. It may be the greatest good deed in the world to put aside the prejudices in his heart about people or things, not to label people easily, and not to make self-righteous remarks about things.
In the movie, Li Jing has been trying to eliminate the world's prejudice against Nezha but never letting Nezha know, not good at words but willing to trade his life for Nezha's life; Mrs. Yin is busy all day cutting off demons and demons, still trying to accompany Nezha's growth, isn't this the epitome of modern parents? A father's love is like a mountain but speechless; a mother's love permeates every minute. In my opinion, the growth of children need to accompany, need to accept and understand, more need is the parents lead by example.
The sentence "My life is up to me " in the play deeply touched my heart. This is not so much a mythical role, but rather every one of us who does not accept our fate; every one who constantly strives to get rid of injustice; every one who grits his teeth and never gives in. There are too many injustices in this world. Some people were born with golden spoons, and some grew up in slums. No matter how hard they work, they can't change it. So what? Who stipulates that children who come out of slums cannot make contributions? Who has stipulated that the rich and powerful childe can hold on to the glory of the family? Therefore, try to be yourself, don't be overwhelmed by secular prejudices and stereotypes; firmly believe that as long as you become strong enough, the colored glasses that look at you will break. (Cao Fangtao)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page